Table 5.

Medication Use at Enrollment and Before Enrollment in SPARC IBD

	Crohn’s Disease		Ulcerative Colitis		IBD Unclassified		Total
	N	%	N	%	N	%	N	%
	2003	100.0%	974	100.0%	52	100.0%	3029	100.0%
At time of enrollment
Aminosalicylates	169	8.4%	350	35.9%	17	32.7%	536	17.7%
Mesalamine	132	6.6%	301	30.9%	15	28.8%	448	14.8%
Sulfasalazine	31	1.5%	37	3.8%	2	3.8%	70	2.3%
Balsalazide	9	0.4%	28	2.9%	0	0.0%	37	1.2%
Biologics	1147	57.3%	372	38.2%	19	36.5%	1538	50.8%
Infliximab	365	18.2%	173	17.8%	6	11.5%	544	18.0%
Adalimumab	335	16.7%	64	6.6%	6	11.5%	405	13.4%
Vedolizumab	167	8.3%	115	11.8%	4	7.7%	286	9.4%
Ustekinumab	236	11.8%	9	0.9%	2	3.8%	247	8.2%
Certolizumab Pegol	39	1.9%	2	0.2%	1	1.9%	42	1.4%
Golimumab	3	0.1%	9	0.9%	0	0.0%	12	0.4%
Natalizumab	2	0.1%	0	0.0%	0	0.0%	2	0.1%
Immunomodulators	458	22.9%	221	22.7%	13	25.0%	692	22.8%
Azathioprine	254	12.7%	135	13.9%	5	9.6%	394	13.0%
Methotrexate	115	5.7%	34	3.5%	6	11.5%	155	5.1%
Mercaptopurine	86	4.3%	28	2.9%	0	0.0%	114	3.8%
Tofacitinib	4	0.2%	22	2.3%	1	1.9%	27	0.9%
Tacrolimus	1	0.0%	3	0.3%	1	1.9%	5	0.2%
Steroid Therapies	151	7.5%	111	11.4%	5	9.6%	267	8.8
Exposure
Aminosalicylates	898	44.8%	612	62.8%	38	73.1%	1548	51.1%
Mesalamine	829	41.4%	587	60.3%	37	71.2%	1453	48.0%
Sulfasalazine	195	9.7%	134	13.8%	12	23.1%	341	11.3%
Biologics	1018	50.8%	313	32.1%	22	42.3%	1353	44.7%
Infliximab	887	44.3%	338	34.7%	20	38.5%	1245	41.1%
Adalimumab	814	40.6%	200	20.5%	16	30.8%	1030	34.0%
Vedolizumab	323	16.1%	190	19.5%	10	19.2%	523	17.3%
Ustekinumab	213	10.6%	15	1.5%	3	5.8%	231	7.6%
Certolizumab Pegol	202	10.1%	8	0.8%	5	9.6%	215	7.1%
Golimumab	16	0.8%	24	2.5%	0	0.0%	40	1.3%
Natalizumab	34	1.7%	1	0.1%	0	0.0%	35	1.2%
Immunomodulators	395	19.7%	111	11.4%	11	21.2%	517	17.1%
Thiopurine	945	47.2%	373	38.3%	20	38.5%	1338	44.2%
Methotrexate	390	19.5%	90	9.2%	8	15.4%	488	16.1%
Tofacitinib	8	0.4%	25	2.6%	5	9.6%	38	1.3%
Steroid Therapies	1205	60.2%	629	64.6%	37	71.2	1871	61.8%